autism diagnosis
The microbiome-based test carries US FDA Breakthrough Device status and is designed to rule out low-risk autism cases early with over 95% negative predictive value.
The study has demonstrated the potential of predictable movement stimuli as a behavioural marker of autism spectrum disorder.
The autism care provider will use the funds to scale nationally and deepen its investments in technology, clinical decision support, data capture and research.
EarliPoint Evaluation monitors a child's looking behavior while watching videos to help a clinician identify autism spectrum disorder.
The proposed system uses brain signals and neural patterns from children.
Cognoa and MedRhythms will be kicking off multi-site investigations of their tools, which are designed for pediatric autism diagnosis and stroke rehabilitation, respectively.